JMIR Publications

ABSTRACT

Obesity has become one of the main public health problems worldwide, due to its association with an increased risk of cardiovascular diseases and type 2 diabetes mellitus. In this context, incretin-based therapies, particularly those that are GLP-1 receptor agonists, are revolutionizing and transforming metabolic management. This is due to their multiple effects, including glycemic regulation, appetite reduction, and assistance in body weight loss, in addition to lowering cardiovascular risk. However, their use presents a series of challenges, both clinical and practical. Among these are the reduction of lean body mass, the need for long-term use, and the potential for weight regain after discontinuation of the medication. Furthermore, their high cost limits their widespread availability globally, making access difficult for countries with limited resources.